Evidence map›Paper›PMID 37187717›Full record

ReviewJournal of clinical medicine research2023

Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review.

Evelyn Calderon-Martinez, Samanta Landazuri-Navas, Esmeralda Vilchez, Raul Cantu-Hernandez, Johanna Mosquera-Moscoso, Sebastian Encalada, Zahraa Al Lami, Christian Zevallos-Delgado, John Cinicola

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of clinical medicine research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. SynchronousWorld journal of gastrointestinal surgery · 2026
    Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Evelyn Calderon-MartinezDepartment of Internal Medicine, UPMC Harrisburg, Harrisburg, PA, USA.ORCID https://orcid.org/0000-0003-0657-6978
Samanta Landazuri-NavasDepartment of Internal Medicine, University of the Americas, Quito, Ecuador.
Esmeralda VilchezDepartment of Internal Medicine, University of Guadalajara, Mexico.
Raul Cantu-HernandezDepartment of Internal Medicine, Monterrey Institute of Technology and Higher Studies, Mexico.
Johanna Mosquera-MoscosoDepartment of Internal Medicine, University of the Americas, Quito, Ecuador.
Sebastian EncaladaDepartment of Internal Medicine, University of the Americas, Quito, Ecuador.
Zahraa Al LamiDepartment of Internal Medicine, University of Baghdad, College of Medicine, Iraq.
Christian Zevallos-DelgadoDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
John CinicolaDepartment of Internal Medicine, UPMC Harrisburg, Harrisburg, PA, USA.
University of the Americas · CLUPMC Central Pa · USTecnológico de Monterrey · MXUniversidad de Guadalajara · MXUniversity of Baghdad · IQUniversity of Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a common cancer and ranks sixth among all malignancies worldwide. Risk factors for HCC can be classified as infectious or behavioral. Viral hepatitis and alcohol abuse are currently the most common risk factors for HCC; however, nonalcoholic liver disease is expected to become the most common cause of HCC in upcoming years. HCC survival rates vary according to the causative risk factors. As in any malignancy, staging is crucial in making therapeutic decisions. The selection of a specific score should be individualized according to patient characteristics. In this review, we summarize the current data on epidemiology, risk factors, prognostic scores, and survival in HCC.

Indexed as

CancerHepatocellularMortalitySurvival

Identifiers

PMID37187717
PMCPMC10181349
OpenAlexW4367314878

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.